By Susana Banerjee, Michael A. Bookman (auth.), Stan Kaye, Robert Brown, Hani Gabra, Martin Gore (eds.)
Despite swift advances in realizing the biology of ovarian melanoma, growth in remedy has been gradual. however the clients for development have by no means been larger. a variety of novel healing ambitions now current themselves for scientific overview and preliminary effects are definitely encouraging. during this textual content, these kind of components are lined through specialists within the box. each one bankruptcy presents updated assurance of medical details, prefaced via an outline of the rational foundation for the choice of every objective quarter and attention of biomarkers that may be used to assist scientific evaluate. The 4 editors interact in the Ovarian melanoma motion collaborative examine programme in London they usually deliver a wealth of laboratory and scientific services to this subject. The textual content may still supply a useful resource of reference for scientific and laboratory-based researchers operating to fulfill the demanding situations of ovarian cancer.
Read or Download Emerging Therapeutic Targets in Ovarian Cancer PDF
Similar cancer books
There can by no means be sufficient fabric within the public area approximately cancers, and especially breast melanoma. This publication provides a lot to the literature. It presents common info on breast melanoma administration and considers all new tools of analysis and treatment. It specializes in nuclear medication modalities via evaluating their effects with different diagnostic and healing methods.
Supplied by way of the sufferers, their neighbors, households, and caregivers of these diagnaosed with lung melanoma, those very own stories offer encouraged perception into the methods households and execs deal with either themselves and the sufferer, achieve a deeper knowing of the relationships, and learn how to come to phrases with the top of lifestyles.
It really is now obvious that numerous fields of research are converging upon one another because the aim of discovering a pragmatic option to hinder melanoma is pursued. the current monograph represents the efforts of an interdisciplinary ESO activity strength that used to be convened to evaluate interactions of peptide development elements and steroid-like molecules within the prevention of melanoma.
- Impact of Genetic Targets on Cancer Therapy
- Endocrine Therapy of Breast Cancer
- Colorectal disease
- Quality July 2011
- Quest for the Cure. Reflections on the Evolution of Breast Cancer Treatment
- Endometrial Cancer
Additional resources for Emerging Therapeutic Targets in Ovarian Cancer
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176–82. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. (2009b). Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
2007). These results compare favourably to previous phase II trials of cytotoxic therapy. 4%) (Han and Monk, 2007). Single-agent bevacizumab is reasonably well tolerated and should be considered for further study as a treatment for recurrent ovarian cancer. In addition, anti-angiogenic agents have the potential to enhance the efficacy of chemotherapy when given as combination treatment. , 2007). This concept is being addressed by two ongoing phase III trials of bevacizumab in combination with carboplatin/paclitaxel in front-line ovarian cancer therapy (Gynaecologic Oncology Group (GOG) trial 218 and International Collaborative Ovarian Neoplasm (ICON)7 trial).
3 EGFR and HER2 Inhibitors The epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 receptor (HER2) are tyrosine kinase receptors involved in cell proliferation and survival. Preclinical evidence suggested that EGFR and HER2 were potential targets in ovarian cancer. , 2007). , 2003). Gordon et al. 9 vs. , 2006). HER2 activation may be a better predictor of sensitivity to HER2-targeted agents than HER2 expression and this is currently under 1 Systemic Therapy for Ovarian Cancer 21 investigation.
Emerging Therapeutic Targets in Ovarian Cancer by Susana Banerjee, Michael A. Bookman (auth.), Stan Kaye, Robert Brown, Hani Gabra, Martin Gore (eds.)